全文获取类型
收费全文 | 212篇 |
免费 | 20篇 |
专业分类
妇产科学 | 3篇 |
基础医学 | 22篇 |
口腔科学 | 1篇 |
临床医学 | 8篇 |
内科学 | 146篇 |
神经病学 | 4篇 |
特种医学 | 2篇 |
外科学 | 10篇 |
综合类 | 2篇 |
预防医学 | 5篇 |
药学 | 28篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 1篇 |
2023年 | 11篇 |
2022年 | 12篇 |
2021年 | 13篇 |
2020年 | 27篇 |
2019年 | 41篇 |
2018年 | 36篇 |
2017年 | 25篇 |
2016年 | 10篇 |
2015年 | 6篇 |
2014年 | 24篇 |
2013年 | 13篇 |
2012年 | 2篇 |
2011年 | 2篇 |
2010年 | 2篇 |
2008年 | 1篇 |
2007年 | 3篇 |
2005年 | 1篇 |
2004年 | 1篇 |
1981年 | 1篇 |
排序方式: 共有232条查询结果,搜索用时 0 毫秒
1.
2.
3.
Julie C. Sung Ciara Bosh Brooke Wyatt Mark Miller Alyson Harty David Del Bello Sterling Knight Douglas T. Dieterich Ponni V. Perumalswami Andrea D. Branch 《Journal of viral hepatitis》2020,27(4):350-359
Patient‐reported outcomes (PROs) are important measures of quality of life. Direct‐acting antiviral (DAA) drugs for hepatitis C virus (HCV) improved PROs in clinical trials. We prospectively evaluated the impact of DAA‐based HCV cure on PROs and liver‐related outcomes in real‐world patients at a large urban medical center. The short form (SF)‐36 and three additional validated instruments were used. F3‐4 fibrosis was defined as > 9.6 kPa by transient elastography (TE); S2‐3 steatosis was defined as > 270 dB/m by TE‐controlled attenuation parameter (CAP). Data were analysed by paired and unpaired t tests. Patients (n = 16) who did not achieve a sustained virologic response at 12 weeks (SVR12) were excluded. The study achieved its primary endpoint and showed a significant 30% improvement in the SF‐36 vitality score, measured baseline to SVR12: 63 versus 82, P < .001 (n = 111). Scores in 24 of 25 PRO domains improved at SVR12 (P < .05). Nearly all gains exceeded 5%, indicating their clinical significance. Transaminase values and liver stiffness improved (decreased) significantly, baseline to SVR12 (P < .005), but steatosis was unchanged (P = .58). Patients with baseline F0‐2 fibrosis and those with F3‐F4 fibrosis both improved in 22 domains. Patients with baseline S0‐S1 steatosis improved in more domains (23) than patients with S2‐S3 steatosis (19). At baseline, patients with F3‐F4 fibrosis and patients with S2‐3 steatosis had worse scores in certain PRO domains than patients with F0‐2 fibrosis or S0‐S1 steatosis, but this difference resolved by SVR12. HCV cure led to meaningful gains in PROs, and these findings may encourage patients to seek treatment. 相似文献
4.
5.
6.
7.
Ivan Gentile Emanuela Zappulo Antonio Riccardo Buonomo Riccardo Scotto Guglielmo Borgia 《Expert opinion on drug safety》2015,14(10):1631-1646
Introduction: The introduction of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV) chronic infection. Non-structural 3 protease inhibitors are currently the most numerous class of DAAs on the market.Areas covered: This review mainly focuses on the tolerability and safety profile of asunaprevir (ASV)-containing DAA regimens. ASV is a second-wave protease inhibitor currently in Phase III clinical development in most countries and already available in Japan.Expert opinion: ASV shows potent antiviral effect and clinical efficacy on HCV genotypes 1 and 4. The all-oral combination daclatasvir/ASV reached high eradication rates in HCV genotype 1b and 4 infection, and a lower efficacy in genotype 1a infection. ASV presents a low potential for drug–drug interaction and a good tolerability as part of multiple, including all-oral, regimens. ASV is associated with a transient and usually mild increase in aminotransferase levels in a low percentage of cases. Due to the impaired pharmacokinetic profile observed in advanced liver disease, ASV use in patients with moderate or severe hepatic impairment is not allowed. In conclusion, ASV represents a powerful weapon against HCV infection and has to be considered an optimal option as a component of genotype tailored interferon-free combinations. 相似文献
8.
9.
10.